Korro Bio to Cut 34% of Jobs After Pausing Novo Nordisk Deal

Dow Jones

Nov 13, 2025

By Katherine Hamilton

Korro Bio plans to reduce its workforce by 34% after pausing its licensing partnership with Novo Nordisk.

The Cambridge, Mass., biopharmaceutical company said Wednesday the job cuts are part of a strategic restructuring. Korro had 104 full-time employees as of December 2024.

Korro expects to incur a one-time charge of $2.4 million related to severance, benefits and termination costs, which the company expects to recognize before the end of the year.

The job cuts come as Korro and Novo Nordisk have agreed to pause their licensing agreement for 12 months. Under the agreement, which was signed in September 2024, Novo Nordisk had an exclusive global license to research, develop and sell certain cardiometabolic products developed by Korro.

During the pause, all research and development activities under the agreement will be suspended, Korro said. Korro is also winding down its research and development activities in connection with the agreement.

Korro is aiming to extend its cash runway into the second half of 2027 to deliver clinical data for KRRO-121, a treatment designed to help patients with hyperammonemia, which is a condition where there is too much ammonia in the blood.

Korro's chief medical Officer Olukemi Olugemo also resigned. Its chief financial officer stepped down in October.

- -

Write to Katherine Hamilton at katherine.hamilton@wsj.com

(END) Dow Jones Newswires

November 12, 2025 17:03 ET (22:03 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2583586490"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2583586490\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2583586490?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 06:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2583586490","market":"hk","top_or_hot":-1,"title":"Korro Bio to Cut 34% of Jobs After Pausing Novo Nordisk Deal","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/KRRO\">Korro Bio</a> plans to reduce its workforce by 34% after pausing its licensing partnership with <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>. \n</p>\n<p>\n  The Cambridge, Mass., biopharmaceutical company said Wednesday the job cuts are part of a strategic restructuring. Korro had 104 full-time employees as of December 2024. \n</p>\n<p>\n  Korro expects to incur a one-time charge of $2.4 million related to severance, benefits and termination costs, which the company expects to recognize before the end of the year. \n</p>\n<p>\n  The job cuts come as Korro and Novo Nordisk have agreed to pause their licensing agreement for 12 months. Under the agreement, which was signed in September 2024, Novo Nordisk had an exclusive global license to research, develop and sell certain cardiometabolic products developed by Korro. \n</p>\n<p>\n  During the pause, all research and development activities under the agreement will be suspended, Korro said. Korro is also winding down its research and development activities in connection with the agreement. \n</p>\n<p>\n  Korro is aiming to extend its cash runway into the second half of 2027 to deliver clinical data for KRRO-121, a treatment designed to help patients with hyperammonemia, which is a condition where there is too much ammonia in the blood. \n</p>\n<p>\n  Korro's chief medical Officer Olukemi Olugemo also resigned. Its chief financial officer stepped down in October. \n</p>\n<pre style=\"white-space: pre\">\n- - \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 12, 2025 17:03 ET (22:03 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Korro Bio to Cut 34% of Jobs After Pausing Novo Nordisk Deal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKorro Bio to Cut 34% of Jobs After Pausing Novo Nordisk Deal\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-11-13 06:03</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Katherine Hamilton \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/KRRO\">Korro Bio</a> plans to reduce its workforce by 34% after pausing its licensing partnership with <a href=\"https://laohu8.com/S/NVO\">Novo Nordisk</a>. \n</p>\n<p>\n  The Cambridge, Mass., biopharmaceutical company said Wednesday the job cuts are part of a strategic restructuring. Korro had 104 full-time employees as of December 2024. \n</p>\n<p>\n  Korro expects to incur a one-time charge of $2.4 million related to severance, benefits and termination costs, which the company expects to recognize before the end of the year. \n</p>\n<p>\n  The job cuts come as Korro and Novo Nordisk have agreed to pause their licensing agreement for 12 months. Under the agreement, which was signed in September 2024, Novo Nordisk had an exclusive global license to research, develop and sell certain cardiometabolic products developed by Korro. \n</p>\n<p>\n  During the pause, all research and development activities under the agreement will be suspended, Korro said. Korro is also winding down its research and development activities in connection with the agreement. \n</p>\n<p>\n  Korro is aiming to extend its cash runway into the second half of 2027 to deliver clinical data for KRRO-121, a treatment designed to help patients with hyperammonemia, which is a condition where there is too much ammonia in the blood. \n</p>\n<p>\n  Korro's chief medical Officer Olukemi Olugemo also resigned. Its chief financial officer stepped down in October. \n</p>\n<pre style=\"white-space: pre\">\n- - \n</pre>\n<p>\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n</p>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 12, 2025 17:03 ET (22:03 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0154236417.USD","symbol_name":"BGF US FLEXIBLE EQUITY \"A2\" ACC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2583586490","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2583586490","pubTimestamp":1762984980,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Korro Bio plans to reduce its workforce by 34% after pausing its licensing partnership with Novo Nordisk.The Cambridge, Mass., biopharmaceutical company said Wednesday the job cuts are part of a strategic restructuring. Korro had 104 full-time employees as of December 2024.Korro expects to incur a one-time charge of $2.4 million related to severance, benefits and termination costs, which the company expects to recognize before the end of the year.The job cuts come as Korro and Novo Nordisk have agreed to pause their licensing agreement for 12 months. Under the agreement, which was signed in September 2024, Novo Nordisk had an exclusive global license to research, develop and sell certain cardiometabolic products developed by Korro.During the pause, all research and development activities under the agreement will be suspended, Korro said. Korro is also winding down its research and development activities in connection with the agreement.Korro is aiming to extend its cash runway into the","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0154236417.USD":"BGF US FLEXIBLE EQUITY \"A2\" ACC","IE00BKVL7J92.USD":"Legg Mason ClearBridge - US Equity Sustainability Leaders A Acc USD","BK4588":"碎股","LU1093756325.SGD":"FTIF - Franklin K2 Alt Strat Fd A (acc) SGD-H1","BK4585":"ETF&股票定投概念","BK4139":"生物科技","BK4532":"文艺复兴科技持仓","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","KRRO":"Korro Bio, Inc.","BK4599":"减肥药","BK4007":"制药","IE00BZ1G4Q59.USD":"LEGG MASON CLEARBRIDGE US EQUITY SUSTAINABILITY LEADER \"A\"(USD) INC (A)"},"translate_title":"暂停诺和诺德交易后Korro Bio将裁员34%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KRRO":0.9},"content_text":"By Katherine Hamilton \n\n\nKorro Bio plans to reduce its workforce by 34% after pausing its licensing partnership with Novo Nordisk. \n\n\n  The Cambridge, Mass., biopharmaceutical company said Wednesday the job cuts are part of a strategic restructuring. Korro had 104 full-time employees as of December 2024. \n\n\n  Korro expects to incur a one-time charge of $2.4 million related to severance, benefits and termination costs, which the company expects to recognize before the end of the year. \n\n\n  The job cuts come as Korro and Novo Nordisk have agreed to pause their licensing agreement for 12 months. Under the agreement, which was signed in September 2024, Novo Nordisk had an exclusive global license to research, develop and sell certain cardiometabolic products developed by Korro. \n\n\n  During the pause, all research and development activities under the agreement will be suspended, Korro said. Korro is also winding down its research and development activities in connection with the agreement. \n\n\n  Korro is aiming to extend its cash runway into the second half of 2027 to deliver clinical data for KRRO-121, a treatment designed to help patients with hyperammonemia, which is a condition where there is too much ammonia in the blood. \n\n\n  Korro's chief medical Officer Olukemi Olugemo also resigned. Its chief financial officer stepped down in October. \n\n\n- - \n\n\n  Write to Katherine Hamilton at katherine.hamilton@wsj.com \n\n\n  (END) Dow Jones Newswires\n\n\n  November 12, 2025 17:03 ET (22:03 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"executive","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}